Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a
nucleoside analog reverse transcriptase inhibitor (NARTI) sold under the trade ...
Easy to read patient leaflet for zalcitabine. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Jan 30, 2009 ... Learn about Hivid (Zalcitabine) may treat, uses, dosage, side effects, drug
interactions, warnings, patient labeling, reviews, and related ...
It was manufactured by Roche. ddC was also known as zalcitabine or
dideoxycytidine. ddC was a nucleoside analog reverse transcriptase inhibitor, or
Jun 13, 2005 ... Zalcitabine inhibits the activity of HIV-1 reverse transcriptase (RT) both by
competing with the natural substrate dGTP and by its incorporation ...
Jan 25, 2001 ... Approval. FDA approval of zalcitabine for use in combination with zidovudine in
adults was granted in 1992. Initial approval was based on trial ...
Find patient medical information for zalcitabine oral on WebMD including its uses
, side effects and safety, interactions, pictures, warnings and user ratings.
ddC; 2',3'-Dideoxycytidine; Hivid; NSC 606170; Ro 24-2027/000. Zalcitabine is
an analog of pyrimidine derived from deoxycytidine with the replacement of the ...
The triphosphate form of zalcitabine inhibits HIV reverse transcriptase by
competing for incorporation into viral DNA as well as chain termination of the viral
a nucleoside analogueantiretroviral agent that inhibits the action of reverse
transcriptase; used in the treatment of human immunodeficiency virus (HIV)